

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number
WO 02/070518 A1

(51) International Patent Classification⁷: **C07D 411/04**,
A61K 31/506, A61P 31/18

(21) International Application Number: PCT/US02/06184

(22) International Filing Date: 1 March 2002 (01.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/272,560 1 March 2001 (01.03.2001) US
60/309,605 2 August 2001 (02.08.2001) US

(71) Applicants (for all designated States except US): **TRI-
ANGLE PHARMACEUTICALS, INC.** [US/US]; 4
University Place, 4611 University Drive, Durham, NC
27707 (US). **ABBOTT LABORATORIES** [US/US];
Department 377, Building AP6P, 100 Abbott Park Road,
Abbott Park, IL 60064-6050 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PHARES, Kenneth,**

R. [US/US]; 194 Amber Wood Run, Chapel Hill, NC 27516
(US). **LAW, Devalina** [IN/US]; 835C Country Club Drive,
Libertyville, IL 60048 (US). **HU, Yuerong** [CN/US]; 705
N. 5th Street, Apartment 22, Lafayette, IN 47901 (US).


(74) Agents: **KNOWLES, Sherry, M.** et al.; King & Spalding,
191 Peachtree Street, Atlanta, GA 30303-1763 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent

[Continued on next page]

(54) Title: POLYMORPHIC AND OTHER CRYSTALLINE FORMS OF CIS-FTC



(57) Abstract: Solid phases of (-)-cis-FTC, which are designated herein as amorphous (-)-FTC and Forms II and III (-)-cis-FTC are provided that can be distinguished from Form I (-)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (±)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.



WO 02/070518 A1



(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Polymorphic and Other Crystalline Forms of cis-FTC

FIELD OF THE INVENTION

The present invention relates to polymorphic and other crystalline forms of
5 (-)- and (±)-cis-FTC (4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-
2(1H)-pyrimidinone), pharmaceutical compositions thereof, and uses for such
compositions.



BACKGROUND OF THE INVENTION

10 The success of various synthetic nucleosides such as AZT, D4T, DDI, and
DDC in inhibiting the replication of HIV *in vivo* or *in vitro* led researchers in the late
1980's to design and test nucleosides that substitute a heteroatom for the carbon atom
at the 3'-position of the nucleoside. Norbeck, *et al.*, disclosed that (±)-1- [cis-(2,4)-2-
(hydroxymethyl)-4-dioxolanyl]thymine (referred to as (±)-dioxolane-T) exhibits a
15 modest activity against HIV (EC₅₀ of 20 μ M in ATH8 cells), and is not toxic to
uninfected control cells at a concentration of 200 μ M. Tetrahedron Letters 30 (46),
6246, (1989). European Patent Application Publication No. 337 713 and U.S. Patent
No. 5,041,449, assigned to BioChem Pharma, Inc., disclose racemic 2-substituted-4-
substituted-1,3-dioxolanes that exhibit antiviral activity. Published PCT application
20 numbers PCT US91/09124 and PCT US93/08044 disclose isolated β -D-1,3-
dioxolanyl nucleosides for the treatment of HIV infection. WO 94/09793 discloses
the use of isolated β -D-1,3-dioxolanyl nucleosides for the treatment of HBV infection.

U.S. Patent No. 5,047,407 and European Patent Application Publication No. 0
382 526, also assigned to BioChem Pharma, Inc., disclose that a number of racemic 2-
25 substituted-5-substituted-1,3-oxathiolane nucleosides have antiviral activity, and
specifically report that the racemic mixture of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-
oxathiolane (referred to below as BCH-189) has approximately the same activity
against HIV as AZT, with less toxicity. The (-)-enantiomer of BCH-189 (U.S. Patent
No. 5,539,116 to Liotta, *et al.*), known as 3TC, is now sold commercially for the
30 treatment of HIV in humans in the United States. See also EP 513 200 B1.

It has also been disclosed that (-)-(cis)-FTC (4-amino-5-fluoro-1-(2-
(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone (2R-cis), or β -L-2-

hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane) has potent HIV activity. See Schinazi, *et al.*, "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl]Cytosine" *Antimicrobial Agents and Chemotherapy*, November 1992, page 2423-2431. See also U.S. Patent Nos. 5,814,639; 5,914,331; 5,210,085; U.S. Patent No. 5,204,466, WO 91/11186, and WO 92/14743. The chemical structure of (-)-cis-FTC is shown below:




Mol. Wt.: 247.25

Because of the commercial importance of 1,3-oxathiolane nucleosides such as FTC, a number of processes for their production have been described in patents and scientific literature. The substituents on the chiral carbons (the specified purine or pyrimidine base (referred to as the C5 substituent)) and CH_2OH (referred to as the C2 substituent)) of 1,3-oxathiolane nucleosides can be either *cis* (on the same side) or *trans* (on opposite sides) with respect to the oxathiolane ring system. Both the *cis* and *trans* racemates consist of a pair of optical isomers. Hence, each compound has four individual optical isomers. The four optical isomers are represented by the following configurations (when orienting the oxathiolane moiety in a horizontal plane such that the $-\text{S}-\text{CH}_2-$ moiety is in back): (1) *cis* (also referred to as β), with both groups "up", which is the naturally occurring L-*cis* configuration (2) *cis*, with both groups "down", which is the non-naturally occurring β -*cis* configuration; (3) *trans* (also referred to as the α -configuration) with the C2 substituent "up" and the C5 substituent "down"; and (4) *trans* with the C2 substituent "down" and the C5 substituent "up". The two *cis* enantiomers together are referred to as a racemic mixture of β -enantiomers, and the

two *trans* enantiomers are referred to as a racemic mixture of α -enantiomers. In general, it is fairly standard to be able to separate the pair of *cis* racemic optical isomers from the pair of *trans* racemic optical isomers. It is a significantly more difficult challenge to separate or otherwise obtain the individual enantiomers of the *cis*-configuration. For 3TC and FTC, the desired stereochemical configuration is the β -L-isomer.

The numbering scheme for the 1,3-oxathiolane ring in FTC is given below.



10 Routes to condense the 1,3-oxathiolane ring with a protected base

U.S. Patent No. 5,204,466 discloses a method to condense a 1,3-oxathiolane with a protected pyrimidine base using tin chloride as a Lewis acid, which provides virtually complete β -stereoselectivity. See also Choi, et al, "In Situ Complexation Directs the Stereochemistry of N-Glycosylation in the synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues," *J. Am Chem. Soc.* 1991, 213, 9377-9379. The use of tin chloride creates undesirable residues and side products during the reaction which are difficult to remove.

A number of U.S. patents disclose a process for the preparation of 1,3-oxathiolane nucleosides via the condensation of a 1,3-oxathiolane intermediate that has a chiral ester at the 2-position of the ring, with a protected base in the presence of a silicon-based Lewis acid. The ester at the 2-position must then be reduced to the corresponding hydroxymethyl group to afford the final product. See U.S. Patent Nos. 5,663,320; 5,864,164; 5,693,787; 5,696,254; 5,744,596; and 5,756,706.

U.S. Patent No. 5,763,606 discloses a process for producing predominantly *cis*-2-carboxylic or thiocarboxylic acid 1,3-oxathiolane nucleosides that includes coupling a desired, previously silylated purine or pyrimidine base with a bicyclic intermediate in the presence of a Lewis acid. U.S. Patent No. 5,272,151 describes a process for the preparation of 1,3-dioxolane nucleosides that includes reacting a 2-O-

protected-5-O-acylated-1,3-dioxolane with an oxygen- or nitrogen-protected purine or pyrimidine base in the presence of a titanium catalyst.

Choi, et al, "In Situ Complexation Directs the Stereochemistry of N-Glycosylation in the synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues," *J. Am Chem. Soc.* 1991, 213, 9377-9379, reported that no coupling of the 1,3-oxathiolane with protected pyrimidine base occurs with HgCl_2 , Et_2AlCl , or $\text{TiCl}_2(\text{O-isopropyl})_2$ (see footnote 2). Choi also reported that the reaction between anomeric 1,3-oxathiolane acetates with silylated cytosine and virtually any common Lewis acid other than tin chloride resulted in the formation of inseparable mixtures of N-glycosylated anomers.

U.S. Patent No. 5,922,867 discloses a method for preparing a dioxolane nucleoside that includes glycosylating a purine or pyrimidine base with a 2-protected-oxymethyl-4-halo-1,3-dioxolane.

U.S. Patent Nos. 5,914,331, 5,700,937, 5,827,727, and 5,892,025, among others, to Liotta *et al.* describe coupling the 1,3-oxathiolanes disclosed therein with silylated 5-fluorocytosine in the presence of SnCl_4 to form the $\beta(-)$ -isomer of FTC; and optionally removing the protecting groups.

Routes to provide the 1,3-oxathiolane nucleoside in the desired stereoconfiguration

Specific methods for preparing FTC in the desired stereoconfiguration in a substantially pure form are described in U.S. Patent Nos. 5,914,331, 5,700,937, 5,827,727, and 5,892,025, among others, to Liotta *et al.* In one embodiment, the C5'-hydroxyl group of a mixture of nucleoside racemates is reacted with an acyl compound to form C5'-esters in which the nucleoside is in the "carbinol" end of the ester. The desired enantiomer can be isolated by treatment of the racemic mixture with an enzyme that hydrolyses the desired enantiomer (followed by extraction of the polar hydrolysate with a polar solvent) or by treatment with an enzyme that hydrolyses the undesired enantiomer (followed by removal of the undesired enantiomer with a polar solvent). Enzymes that catalyze the hydrolysis of 1,3-oxathiolane pyrimidine nucleosides include pig liver esterase, porcine pancreatic lipase, Amano PS-800 lipase, subtilisin, and α -chymotrypsin.

Cytidine-deoxycytidine deaminase can be used to resolve racemic mixtures of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane and its derivatives, including 2-

hydroxymethyl-5-(5-fluoro-cytosin-1-yl)-1,3-oxathiolane. The enzyme catalyses the deamination of the cytosine moiety to a uridine. One of the enantiomers of 1,3-oxathiolane nucleosides is a preferred substrate for cytidine-deoxycytidine deaminase. The enantiomer that is not converted to a uridine (and therefore is still basic) is
5 extracted from solution with an acidic solution. Cytidine-deoxycytidine deaminase can be isolated from rat liver or human liver, or expressed from recombinant sequences in a procaryotic system such as *E. coli*.

Chiral chromatography can also be used to resolve cis-FTC enantiomers. For example, U.S. Patent No. 5,892,025 to Liotta, *et al.* discloses a method for resolving a
10 combination of the enantiomers of cis-FTC by passing the cis-FTC through an acetylated β -cyclodextrin chiral column.

Polymorphic Characterization

The ability of a compound to exist in different crystal structures is known as polymorphism. These different crystalline forms are known as "polymorphic
15 modifications" or "polymorphs." While polymorphs have the same chemical composition, they differ in packing and geometrical arrangement, and exhibit different physical properties such as melting point, shape, color, density, hardness, deformability, stability, dissolution, and the like. Depending on their temperature-stability relationship, two polymorphs may be either monotropic or enantiotropic. For
20 a monotropic system, the relative stability between the two solid phases remains unchanged as the temperature is changed. In contrast, in an enantiotropic system there exists a transition temperature at which the stability of the two phases reverse. (Theory and Origin of Polymorphism in "Polymorphism in Pharmaceutical Solids" (1999) ISBN: 0-8247-0237).

25 A number of compounds have been reported to exhibit polymorphism. As an early example; Gordon, *et al.* in U.S. Pat. No. 4,476,248, disclosed and claimed a new crystalline form of the drug ibuprofen as well as a process for producing it. The new crystalline form was reported to improve the manufacturability of ibuprofen. A structure more closely related to FTC, 3TC ((-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidine-2-one; lamivudine), is also reported to exist in more
30 than one crystalline form. Jozwiakowski, M.J., Nguyen, N.T., Sisco, J.M., Spancake, C.W. "Solubility Behavior of Lamivudine Crystal Forms in Recrystallization Solvents", *J. Pharm. Sci.*, 85, 2, p.193-199 (1996). See also U.S. Pat. No. 5,905,082

to Roberts *et al.*, entitled "Crystalline Oxathiolane Derivatives," issued May 18, 1999, and its PCT counterpart PCT/EP92/01213, describing two polymorphic forms of 3TC. Roberts *et al.* disclose that one polymorph is obtained when 3TC is crystallized from an aqueous solution. A second polymorph is obtained when 3TC is crystallized from non-aqueous media, or when the first form is melted and allowed to cool, or when the first form is ground or milled. Both polymorphic forms display unique absorption bands, melting temperatures, and crystal energies.

(-)-cis-FTC produced by the above described methods has a distinct crystalline form, referred to herein as Form I (-)-cis-FTC. The angular positions (two theta) of the characteristic peaks in a powder X-ray diffraction pattern of (-) cis Form I FTC, shown in Figure 7, are: $14.1^{\circ} \pm 0.1^{\circ}$, $19.9^{\circ} \pm 0.1^{\circ}$, $20.2^{\circ} \pm 0.1^{\circ}$, $20.6^{\circ} \pm 0.1^{\circ}$, $21.0^{\circ} \pm 0.1^{\circ}$, $22.4^{\circ} \pm 0.1^{\circ}$, $28.5^{\circ} \pm 0.1^{\circ}$, $29.5^{\circ} \pm 0.1^{\circ}$, and $32.6^{\circ} \pm 0.1^{\circ}$.

Additional polymorphs and other crystalline forms of FTC could have commercial value in manufacturing or other applications. It is therefore an objective of this invention to provide novel polymorphic and other crystalline forms of FTC.

It is another objective to provide novel methods for the preparation and isolation of polymorphic and other crystalline forms of FTC.

It is still another objective of the invention to provide therapeutic uses of FTC polymorphs and other phases of FTC.

SUMMARY OF THE INVENTION

Solid phases of (-)-cis-FTC, which are designated herein as amorphous (-)-FTC and Forms II and III (-)-cis-FTC) are provided that can be distinguished from Form I (-)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (\pm)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.

Form II (-)-cis-FTC can be obtained by melting Form I (-)-cis-FTC and allowing the melt to recrystallize at a temperature close to the melting point of Form I. Form III (-)-cis-FTC can be obtained by cooling Form II (-)-cis-FTC below the

thermodynamic transition temperature for forms II and III. Amorphous (-)-cis-FTC can be obtained by rapidly cooling liquid (-)-cis-FTC. The hydrated crystalline form of (\pm)-cis-FTC is a sesquihydrate, and may be obtained by dissolving (\pm)-cis-FTC in water and recrystallizing the FTC. The dehydrated form of the sesquihydrate can be
5 obtained by removing the waters of hydration from the sesquihydrate.

BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1 is a typical DSC ("differential scanning calorimetry") thermogram of (-)-cis-FTC Form I, with an endotherm at 151°C, obtained by heating at a rate of 10
10 °C/min.

FIGURE 2 is a DSC thermogram of (-)-cis-FTC Form I obtained by heating at 1 °C/min.

FIGURE 3 is a DSC thermogram of (-)-cis-FTC Form I obtained by heating at 2 °C/min.

15 FIGURE 4 is a DSC thermogram of (-)-cis-FTC Form I obtained by heating at 5 °C/min.

FIGURE 5 is a DSC thermogram of Form II and III (-)-cis-FTC.

FIGURE 6 is a DSC thermogram showing that the Form II to III transition is reversible.

20 FIGURE 7 is a PXRD ("powder X-ray diffraction") pattern of Form I (-)-cis-FTC.

FIGURE 8 is a PXRD pattern of Form II (-)-cis-FTC.

FIGURE 9 is a PXRD pattern of Form III (-)-cis-FTC.

FIGURE 10 is a PXRD pattern of the sesquihydrate of (\pm)-cis-FTC.

25 FIGURE 11 is a PXRD pattern of a dehydrated form of racemic cis-FTC sesquihydrate.

FIGURE 12 is a DSC thermogram of (\pm)-cis-FTC sesquihydrate and (-)-cis-FTC.

FIGURE 13 is a TGA ("thermogravimetric analysis") scan of the
30 sesquihydrate of (\pm)-cis-FTC.

FIGURE 14 is a free energy-temperature relationship for three polymorphs of (-)-(cis)-FTC (Forms I, II, and III). The stable phases are represented by a solid line and the metastable phases by a dotted line.

Figure 15 is a DSC thermogram of amorphous (-)-cis-FTC obtained by melting and freezing a crystalline sample of (-)-cis-FTC. The final heating rate was 10 °C/min.

DETAILED DESCRIPTION OF THE INVENTION

Two new polymorphic forms of (-)-cis-FTC, the amorphous phase of (-)-cis-FTC, one new hydrated crystalline form of (±)-cis-FTC, and a dehydrated form of the (±)-cis-FTC hydrate are provided that can be distinguished from other phases of (-)-cis-FTC and (±)-cis-FTC by X-ray diffraction patterns, thermal properties, and the methods by which they are made. These forms of FTC along with the amorphous phase can be used as intermediates in the manufacture of FTC, or can be formulated into pharmaceutical compositions and used for the treatment of HIV or hepatitis B.

The two polymorphic forms of (-)-cis-FTC of this invention are designated Forms II and III (-)-cis-FTC, and are characterized by the X-ray powder diffraction patterns in Figures 8 and 9. These forms should be contrasted with Form I (-)-cis-FTC, which is the polymorphic form of (-)-cis-FTC prepared by the methods described in the background section of this document. Form I (-)-cis-FTC can be characterized by the X-ray powder diffraction pattern shown in Figure 7, or by the peaks at the diffraction angles given in the background section of this document.

The hydrated crystalline form of (±)-cis-FTC is characterized by the X-ray powder diffraction patterns in Figure 10. This form should be contrasted with the (±)-cis-FTC manufactured in the prior art. The thermal properties for the various forms are summarized in the table below:

Type of transition $T_{\text{transition}}^{\text{phase}}$	Approximate temperature (°C)	Temperature Range (°C)
T_m^{I}	151	148-153
T_m^{II}	166	162-167
T_m^{III}	Not observed in this	Not observed

	investigation	
$T_g^{\text{Amorphous}}$	67	+/- 3°C at 10°C/min heating rate
$T_t^{I,II}$	130 (calculated)	N/A
$T_t^{II,III}$	102	96-112
T_d^{hydrate}	>30	--
T_m^{racemate}	190	185-192

Thus, the invention provides:

- a) two polymorphs and an amorphous phase of (-)-cis-FTC, as characterized by X-ray powder diffraction analysis, physical properties, and methods of manufacture;
- b) a hydrated crystalline form of (±)-cis-FTC, and dehydrated form of the (±)-cis-FTC hydrate, as characterized by X-ray powder diffraction analysis, physical properties, and methods of manufacture;
- c) processes for making the (-)-cis-FTC phases and the (±)-cis-FTC crystalline forms;
- d) therapeutic and/or pharmaceutical compositions of the (-)-cis-FTC phases and (±)-cis-FTC crystalline forms, optionally in the presence of a pharmaceutically acceptable carrier; and
- e) novel therapeutic uses for the (-)-cis-FTC phases and the (±)-cis-FTC crystalline forms, especially in the treatment of viral diseases such as HIV and hepatitis B.

Form II (-)-cis-FTC

Form II (-)-cis-FTC is observed when Form I (-)-cis-FTC is melted and allowed to recrystallize. Like all polymorphs, Form II can be characterized by the powder diffraction pattern it exhibits when subjected to powder X-ray crystallography. The angular positions (two theta) of the characteristic peaks in the powder X-ray diffraction pattern of Form II (-)-cis-FTC, shown in FIG. 8, are: 14.7°

$\pm 0.1^\circ$, $16.7^\circ \pm 0.1^\circ$, $19.6^\circ \pm 0.1^\circ$, $21.1^\circ \pm 0.1^\circ$, $21.8^\circ \pm 0.1^\circ$, $24.6^\circ \pm 0.1^\circ$, and $25.6^\circ \pm 0.1^\circ$.

Form II (-)-cis-FTC can also be characterized by its melting temperature and/or heat of fusion. Form II (-)-cis-FTC has a melting temperature of about 166°C at atmospheric pressure, and typically exhibits heat of fusion in the range of about 15-19 kJ/mol. It is known that heat of fusion can vary depending on experimental conditions.

Alternatively, Form II (-)-cis-FTC can be characterized by its enantiotropic behavior and the method by which it is manufactured. Form II (-)-cis-FTC is enantiotropic with Form I and Form III polymorphs of (-)-cis-FTC, in the sense that a transition temperature exists below and above which the stability order is reversed. Due to this enantiotropic behavior, Form II (-)-cis-FTC may be prepared from either Form I (-)-cis-FTC or Form III (-)-cis-FTC. In the examples presented in this document, Form II (-)-cis-FTC was obtained:

(1) By heating (-)-cis-FTC (Form I) to above its melting temperature (about 151°C for Form I), and holding it at that elevated temperature. Upon slow cooling, the melted (-)-cis-FTC recrystallized to Form II, and assumed the crystalline form of Form II, at temperatures greater than the thermodynamic transition temperature between Forms II and III.

(2) By heating Form III (-)-cis-FTC to above the thermodynamic transition temperature for Forms II and III, which ranges from about 96°C to about 112°C (because Form II is enantiotropic with Form III (-)-cis-FTC).

Thus, one can obtain Form II (-)-cis-FTC when Form I (-)-cis-FTC is melted and the temperature of the melt is maintained below the melting temperature of Form II but greater than the thermodynamic transition temperature between Forms II and III. Notably, a similar transition from Form II is not observed when Form II is heated to above its melting point (about 166°C) and allowed to slowly cool. Rather, Form II simply recrystallizes to Form II. However, Form II would not crystallize from the same melt if it was quench cooled; rather, an amorphous phase would result.

Therefore, in one embodiment the invention provides Form II (-)-cis-FTC, preferably in substantially pure form, as characterized by any of the foregoing methods. In another embodiment the invention provides Form II (-)-cis-FTC substantially in the absence of Form I (-)-cis-FTC. In still another embodiment the

invention provides Form II (-)-cis-FTC substantially in the absence of Form III (-)-cis-FTC. In yet another embodiment the invention provides a pharmaceutical composition that comprises Form II (-)-cis-FTC, further comprising a pharmaceutically acceptable carrier.

5

Form III (-)-cis-FTC

Because Form II (-)-cis-FTC undergoes a solid state transition to Form III (-)-cis-FTC, this form is obtained from Form II (-)-cis-FTC when the temperature of Form II (-)-cis-FTC is dropped below the transition temperature, which ranges from about 96°C to about 112°C. Form III (-)-cis-FTC is another polymorph of (-)-cis-FTC, and can be characterized by the powder diffraction pattern it exhibits when subjected to powder X-ray crystallography. The angular positions (two theta) of the characteristic peaks in the powder X-ray diffraction pattern of Form III (-)-cis-FTC, shown in FIG. 9, are: 14.5° ± 0.1°, 16.7° ± 0.1°, 19.6° ± 0.1°, 20.4° ± 0.1°, 21.4° ± 0.1°, 21.7° ± 0.1°, 25.2° ± 0.1°, and 26.2° ± 0.1°.

15

Form III (-)-cis-FTC can also be characterized by the methods of its manufacture. Because of Form III's enantiotropic behavior with Form II, Form III (-)-cis-FTC can be prepared from Form II (-)-cis-FTC by cooling Form II (-)-cis-FTC below the solid-state transition temperature for Forms II and III, and thereby causing a solid state transition from Form II (-)-cis-FTC. Of course, Form III (-)-cis-FTC can also be prepared directly from Form I (-)-cis-FTC, with Form II as an intermediate, by melting Form I and slowly cooling the melt to below the solid-state transition temperature for Forms II and III. Because of this stability below its solid state transition temperature, Form III (-)-cis-FTC can also be characterized by the range of temperatures over which it exhibits a solid state transition, but is preferably characterized at the lower end of this range (i.e. about 96 °C at atmospheric pressure).

Therefore, in one embodiment the invention provides Form III (-)-cis-FTC, preferably in substantially pure form. In another embodiment the invention provides Form III (-)-cis-FTC substantially in the absence of Form I (-)-cis-FTC. In another embodiment the invention provides Form III (-)-cis-FTC substantially in the absence of Form II (-)-cis-FTC. In yet another embodiment the invention provides a pharmaceutical composition that comprises Form III (-)-cis-FTC, further comprising a pharmaceutically acceptable carrier.

20

(±)-cis-FTC sesquihydrate

(±)-cis-FTC sesquihydrate is a crystalline form of racemic cis-FTC that is obtained when (±)-cis-FTC is dissolved in water and recrystallized. Notably, the hydrate only results from the racemate of cis-FTC, and does not result from pure (-)-cis-FTC. The (±)-cis-FTC sesquihydrate can be characterized by the powder diffraction pattern it exhibits when subjected to powder X-ray crystallography. The angular positions (two theta) of the characteristic peaks in the powder X-ray diffraction pattern of (±)-cis-FTC sesquihydrate, shown in FIG. 10, are: 11.5° ± 0.1°, 13.4° ± 0.1°, 19.1° ± 0.1°, 20.3° ± 0.1°, 20.8° ± 0.1°, 21.5° ± 0.1°, 21.9° ± 0.1°, and 30.9° ± 0.1°.

The TGA analyses confirm a sesquihydrate of (\pm)-cis-FTC. The sesquihydrate begins to lose its water of hydration to evaporation at about 30° C at atmospheric pressure.

(\pm)-cis-FTC sesquihydrate can also be characterized by one of the methods for its preparation. (\pm)-cis-FTC sesquihydrate is preferably prepared simply by dissolving (\pm)-cis FTC in water, and recrystallizing the dissolved FTC to a hydrated crystalline form. Heat can be employed during dissolution to increase the amount of FTC that is dissolved. The (\pm)-FTC can be present in a pure racemic mixture of cis-FTC, or as an impurity to a composition that comprises mostly (+)-cis-FTC or (-)-cis-FTC. When present as an impurity, (\pm)-FTC preferably comprises at least about 4% by weight of the (+)-cis-FTC or (-)-cis-FTC composition (i.e. if present as an impurity of (-)-cis-FTC, the FTC preferably comprises at least 2% of the (+) enantiomer by weight, and if present as an impurity of (+)-cis-FTC, the FTC preferably comprises at least 2% of the (-) enantiomer by weight).

A DSC thermogram of (\pm)-cis-FTC is shown in Figure 12. The recrystallized FTC is a sesquihydrate, as shown by DSC, TGA, and PXRD analysis.

Therefore, in one embodiment, the invention provides (\pm)-cis-FTC sesquihydrate, preferably in substantially pure form. In still other embodiments, the invention provides (\pm)-cis-FTC sesquihydrate substantially in the absence of Form I (-)-cis-FTC, or substantially in the absence of other hydrated and dehydrated crystalline forms of racemic cis-FTC, (-)-cis-FTC, or (+)-cis-FTC. In still another embodiment the invention provides a pharmaceutical composition that comprises (\pm)-cis-FTC sesquihydrate, further comprising a pharmaceutically acceptable carrier.

Upon evaporating the waters of hydration from (\pm)-cis-FTC sesquihydrate, a dehydrated crystalline form of racemic cis-FTC is formed. The racemic cis-FTC thus obtained can be characterized by the powder diffraction pattern it exhibits when subjected to powder X-ray crystallography. The angular positions (two theta) of the characteristic peaks in the powder X-ray diffraction pattern of dehydrated racemic cis-FTC, shown in FIG. 11, are: $12.3^\circ \pm 0.1^\circ$, $14.0^\circ \pm 0.1^\circ$, $20.7^\circ \pm 0.1^\circ$, $22.6^\circ \pm 0.1^\circ$, $23.3^\circ \pm 0.1^\circ$, and $25.5^\circ \pm 0.1^\circ$. The dehydrated racemic cis-FTC has a melting temperature of about 190 °C at atmospheric pressure, and a heat of fusion of about 23 kJ/mol.

The DSC thermogram in Figure 12 is (\pm)-cis-FTC sesquihydrate. As confirmed by TGA analysis, the large endotherm at about 80 °C was from (\pm)-cis-

FTC sesquihydrate losing its water of hydration. The second endotherm at 190 °C is the melt of the dehydrated racemic cis-FTC.

Thus, in still another embodiment the invention provides the dehydrated (±)-cis-FTC of the present invention. In other embodiments the invention provides the dehydrated (±)-cis-FTC substantially in the absence of Form I (-)-cis-FTC, or substantially in the absence of other hydrated and dehydrated crystalline forms of racemic cis-FTC, (-)-cis-FTC, or (+)-cis-FTC. In still another embodiment the invention provides a pharmaceutical composition that comprises the dehydrated (±)-cis-FTC of the present invention, further comprising a pharmaceutically acceptable carrier.

Amorphous (-)-cis-FTC

An amorphous form of (-)-cis-FTC is obtained when melted (-)-cis-FTC is rapidly quenched to below about 40 or 50 °C, thereby bypassing any transition to Forms II or III (-)-cis-FTC. A DSC thermogram of amorphous (-)-cis-FTC is presented as Figure 15, which shows that the glass transition temperature for this phase is 67 °C.

Therefore, in still another embodiment, the invention provides amorphous (-)-cis-FTC, preferably in substantially pure form. In another embodiment the invention provides amorphous (-)-cis-FTC substantially in the absence of Forms I, II, and/or III (-)-cis-FTC. In still another embodiment the invention provides a pharmaceutical composition that comprises amorphous (-)-cis-FTC, further comprising a pharmaceutically acceptable carrier.

Definitions

As used herein, the term, "substantially pure," when used in reference to a phase or crystalline form of FTC, refers to a phase or crystalline form of FTC which is greater than about 95% pure. This means that the polymorphic or hydrated form of FTC does not contain more than about 5% of any other compound and, in one embodiment, does not contain more than about 5% of any other phases or crystalline forms of FTC (whether racemic, (-), (+), cis, or trans). In other embodiments, the term "substantially pure" refers to a phase or crystalline form of FTC that is greater

than about 96% pure. In still another embodiment the term "substantially pure" refers to a phase or crystalline form of FTC that is greater than about 97% or 99% pure.

Similarly, the term "substantially in the absence of a second component," when used in reference to a phase or crystalline form of FTC, refers to a phase or crystalline form of FTC that does not contain more than about 5% of the second component. More preferably, the term "substantially in the absence of a second component" refers to a phase or crystalline form of FTC that does not contain more than about 4% of the second component, and even more preferably no more than about 3% or 1% of the second component.

Characteristic power X-ray diffraction pattern peak positions are reported for crystalline forms in terms of the angular positions (two theta) within an allowable variability of plus or minus 0.1°. This allowable variability is specified by the US Pharmacopeia, pages 1843-1844 (1995). The variability of plus or minus 0.1° is intended to be used when comparing two powder X-ray diffraction patterns. In practice, if a diffraction pattern peak from one pattern is assigned a range of angular positions (two theta) which is a measured peak position plus or minus 0.1° and a diffraction pattern peak from the other pattern is assigned a range of angular positions (two theta) which is the measured peak position plus or minus 0.1° and if those ranges of peak positions overlap, then the two peaks are considered to have the same angular position (two theta). For example, if a diffraction pattern peak from one pattern is determined to have a peak position of 5.20°, for comparison purposes the allowable variability allows the peak to be assigned a position in the range of 5.10°-5.30°. If a comparison peak from the other diffraction pattern is determined to have a peak position of 5.35°, for comparison purposes the allowable variability allows the peak to be assigned a position in the range of 5.25°-5.45°. Because there is overlap between the two ranges of peak positions, the two peaks being compared are considered to have the same angular position (two theta).

Throughout this specification the word 'comprise,' or variations such as 'comprises' or 'comprising,' will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

EXAMPLES

Materials and Methods

(-)-cis-FTC starting material for all tests, unless otherwise specified, was obtained by combining and treating two batches of (-)-cis-FTC as follows. A flask was charged with 1109 grams of (-)-cis-FTC and 2750-mL of ethyl acetate. This slurry was stirred at ambient temperature for two hours, filtered and washed with 550-mL of ethyl acetate. The filter cake was dried in a vacuum oven overnight at 50 °C and about 2-mm Hg. All solvents were HPLC grade and used as received. An HPLC assay of the starting (-)-cis-FTC indicated a purity of 98.8%.

Differential scanning calorimetry (DSC): The DSC experiments were conducted using one of the following instruments:

DSC studies were conducted using a TA Instruments DSC 2920 (with refrigerated cooling). Approximately 5-mg samples were placed in sealed aluminum pans. The DSC cell was purged with 30-mL/min nitrogen. The heating rate was 10°C/min unless otherwise noted. Temperature and heat flow calibrations were performed with an indium standard at the same experimental conditions.

DSC measurements were made in a Mettler DSC30, (Mettler Instrument, Hightstown, NJ), equipped with a data analyzer (STAR^c, Mettler Instrument). The samples (ca. 2-5 mg) were sealed in standard 40 µL aluminum pans with a single hole punched in the lid. An empty pan of the sample type was used as a reference. The samples were scanned at 1-10°C/min with a 50 mL/min dry nitrogen purge. The DSC was calibrated for heat flow and temperature.

Thermogravimetric analysis (TGA): TGA studies were conducted with a TA Instruments TGA 2950. Approximately 5-mg samples were placed in open platinum pans and the sample was exposed to a heating rate of 10°C/min.

Variable-Temperature PXRD: The diffractometer (XDS 2000, Scintag, Sunnyvale, CA) was comprised of a 4-kW generator (voltage 45 kV and current 40 mA) with a Cu anode tube, liquid nitrogen cooled Ge detector (GLP-10195/07-S, EG&G ORTEC, Oak Ridge, TN), data analyzer (MicroVax 3100, Digital Equipment Corporation, Ontario, Canada), heating stage (Scintag) and temperature controller (Microstar, Research Inc., Minneapolis, MN). The samples were placed on the sample holder in a thin layer, and scanned at a rate of 1° per minute without spinning.

Hot-Stage Microscopy (HSM): Polarized light microscopy was performed using an Olympus BX60 microscope equipped with a Mettler-Toledo FP82HT hot stage. A thin layer of sample was placed on a slide and heated at 10°C/min. Thermal events were captured on ImagePro® software.

5 *Recrystallization method:* About 5 grams of (-)-cis-FTC were placed in a round-bottom flask and heated in the temperature range from 155 to 160°C for 30 minutes with agitation. The sample was cooled in the flask to room temperature at ambient conditions.

10 *Equilibrium Solubility:* Equilibrium solubility values were obtained using an excess of solid in a stoppered flask shaken in a temperature-controlled water bath at 25°C for 52 hours. Residual solid material was identified postequilibrium by hot-stage microscopy and PXRD. The supernatant was filtered across 0.45-µm membrane filters prior to dilution for HPLC analysis.

15 *Milling:* (-)-cis-FTC was milled in a Fitzpatrick mill at high speed (4000 RPM), hammers forward with a 000-band screen. The drug was passed through the filter once and collected in a plastic bag.

20 *Hydrate Formation:* A supersaturated solution (0.5g/mL) of Form I was prepared at 50°C. This solution was then cooled to room temperature with stirring for a ca. 2 hours. The precipitated solid was vacuum filtered and air dried. This solid was analyzed by HPLC, DSC, PXRD and TGA. This analysis revealed that the solid was a sesquihydrate of (±)-cis-FTC.

25 *Crystallization:* (-)-cis-FTC was dissolved in one of the following solvents: methanol, ethyl acetate, water, tetrahydrofuran, and acetone. Each suspension was boiled for about 15 minutes and immediately filtered across a 0.45-µm nylon filter. The supernatant was stirred at room temperature until crystallization. At the point of crystallization, the suspensions were filtered to collect the filter cake. The filter cake was placed in a glass dish, covered with a lint-free paper towel and placed in a hood at ambient conditions for 2 days.

30 **Example 1: DSC Characterization of (-)-cis-FTC Forms I and II**

Thermal events of (-)-cis-FTC polymorph Form I were observed at heating rates of 10, 1, 2, and 5 °C/min. These DSC thermograms are shown in Figures 1, 2, 3,

and 4, respectively. Sample sizes were 6.8400mg, 5.290mg, 5.0430mg, or 5.1500 mg, respectively.

The endotherm at 151 °C corresponds to the melt temperature of (-)-cis-FTC Form I. This endotherm was present at all heating rates studied. The heat of fusion associated with the melt of this phase is 25 kJ/mol. This melting is followed by recrystallization to a higher melting solid, Form II. The presence of the high-temperature endotherm (162 °C) was dependent on the heating rate. Specifically, as the heating rate decreased, the probability increased that the high-temperature endotherm would appear. Also, the heat of fusion value increased for the high-temperature endotherm as the heating rate decreased. These observations are consistent with the fact that at slower heating rates the liquid recrystallizes to a greater extent. This heating-rate-dependent endotherm indicated that Form I may undergo recrystallization after melting at 151°C, and that the resulting crystal form melts at about 162°C. The phase that melts at 162°C was designated “(-)-cis-FTC Form II.”

Example 2: DSC Characterization of (-)-cis-FTC Forms II and III

Thermal events for Form I (-)-cis-FTC upon melting and subsequent cooling to room temperature were observed by DSC. A 5.5500 mg sample of Form I (-)-cis-FTC was heated to 160 °C, that is just above the melting temperature for Form I, and then cooled back to 25 °C. When reheated in the DSC using a heating rate of 10 °C/min, the endotherm at 151 °C for Form I (-)-cis-FTC was not present. However, endotherms did appear at 102 °C and 162 °C, as shown in Figure 5. The endotherm at 102 °C was a solid state transition of Form III (-)-cis-FTC to Form II (-)-cis-FTC as shown in Figure 6. The PXRD data (Figures 7 and 9) collected above and below the 102 °C transition confirmed the DSC interpretation. The endotherm at 162 °C was the melt of Form II (-)-cis-FTC. HPLC confirmed that there was no change in potency associated with these thermal events.

Example 3: DSC Characterization of Amorphous (-)-cis-FTC

A 7.315 mg of Form I FTC was heated to 180°C at 5 °C/min in the DSC. Then the sample was quench cooled at -20 °C/min to -20 °C. This sample when re-heated at 10 °C/min showed a shift in baseline associated with glass transition at ~67 °C. This

shift in baseline occurred during both the heating and cooling cycle confirming that it was due to glass transition. A DSC thermogram of the amorphous (-)-cis-FTC is contained in Figure 15.

5 **Example 4: HSM Observations of Forms I, II, and III (-)-cis-FTC**

The assignment of Forms I, II and III based upon thermal events observed during DSC analysis was consistent with HSM observations. Under the microscope, Form I material appeared as plates at room temperature. Upon heating to 160 °C at 10 °C/min, Form I melted to a clear liquid. On cooling this liquid, acicular needles
10 crystallized from the melt, which were darker in appearance compared to Form I. On reheating, these needles underwent a change in birefringence beginning at about 102 °C and ending at about 115 °C. The needles eventually melted at 166 °C.

Example 5: Effect of milling on crystal form

15 Two batches of milled Form I (-)-cis-FTC were prepared: one by hand trituration in a mortar and pestle for 5 minutes, another by milling in a Fitzpatrick mill. Although not quantitatively measured, light microscopy revealed that the particle size of triturated (-)-cis-FTC appeared smallest followed by that obtained using the Fitzpatrick mill and then unmilled (-)-cis-FTC. The DSC thermogram of
20 sample milled by Fitzpatrick mill and unmilled (-)-cis-FTC had only one endotherm at 151 °C. Triturated (-)-cis-FTC had two endotherms at 151 °C and 162 °C. The PXRD pattern of the triturated (-)-cis-FTC at room temperature was the same as the pattern for Form I, which indicated that conversion from Form I to II occurred during the DSC experiment. Taken together, these data indicate that milling according to the
25 described conditions does not affect the crystal form of (-)-cis-FTC when starting with Form I.

Example 6: Effect of heat on crystal form

The PXRD pattern for Form III at 25 °C and 95 °C, is shown in Figure 9.
30 However, a PXRD pattern of this sample acquired at 120 °C was different from the pattern acquired at 95 °C. The PXRD pattern change over this temperature range was consistent with the endotherm obtained at about 102 °C by DSC thermogram analysis

(Figure.6), and confirms that the 102 °C endotherm was caused by a solid-state transition or change in crystal structure.

The PXRD pattern measured at 120 °C was the same as that measured at 160 °C. However, upon cooling the sample back to 25 °C, the PXRD pattern was the same as Form III (-)-cis-FTC. The crystal form that exists above 102 °C and melts at 162 °C was identified as Form II. The PXRD pattern for Form I material did not change up to the melting temperature of 151 °C.

Example 7: Thermodynamic Stability Analysis

The melting data for Forms I, II, and III, (-)-cis-FTC, are summarized in Table I. Based on this data the thermodynamic relationship between Forms I and II was established. These forms are enantiotropically related and the calculated transition temperature is 130°C.

Table I: Transition temperature data for four crystalline forms of (-)-cis-FTC.

Form	Transition Temperature (°C)	Heat of Fusion (kJ/mol)
I	151	25
II	166	18
III*	102	—
Racemic cis-FTC	186	22.8

* Form III does not undergo melting but rather a solid-state transition at about 112 °C, therefore heat of fusion is not known.

The thermodynamic stability relationship between these forms are graphically depicted in Figure 14.

Example 8: Solubility

It is evident from Figure 14 that below 130°C, Form I is the most stable phase. Therefore, below 130°C, Form I is the least soluble phase. The equilibrium solubility for Form I in water at 25 °C was 0.482 M (119 mg/mL). Compounds having solubility values greater than 100mg/mL are considered highly soluble and (-)-cis-FTC Form I falls in this category. The other forms of (-)-cis FTC described here would have solubility greater than Form I.

Example 9: Crystallization Studies

The (-)-cis-FTC starting material for all crystallization studies was Form I (-)-cis-FTC as determined by PXRD. Form I (-)-cis-FTC was recrystallized from solutions of water, methanol, tetrahydrofuran, ethyl acetate, and acetone. All samples from the crystallization experiments were analyzed by PXRD and DSC. (-)-cis-FTC crystallized from ethyl acetate and acetone exhibited endotherms at 151 °C and 162 °C, and PXRD patterns identical to the pattern for Form I (-)-cis-FTC.

A supersaturated solution (0.5g/mL) of Form I was prepared at 50°C. This solution was then cooled to room temperature with stirring for a *ca.* 2 hours. The precipitated solid was vacuum filtered and air dried. This solid was analyzed by HPLC, DSC, PXRD and TGA. This analysis revealed that the solid was a sesquihydrate of (±)-cis-FTC. The equilibrium solubility of the sesquihydrate at 25 °C is 0.34 M (93 mg/mL). The DSC thermogram of the hydrate is shown in Figure 12. The large endotherm at low temperatures was due to loss of water of hydration from (±)-cis-FTC sesquihydrate, which was confirmed by TGA (Figure 13). The endotherm at 190 °C was due to the melt of the dehydrated hydrate. The dehydrated hydrate was subsequently assigned a unique melting temperature of about 190 °C, Figure 12. A unique PXRD pattern was also collected for the dehydrated hydrate. (See Figure 11)

PHARMACEUTICAL COMPOSITIONS

Humans suffering from HIV and HBV can be treated by administering to the patient an effective amount of the various compounds of the present invention (i.e. Forms II and III (-)-cis FTC, racemic cis-FTC sesquihydrate, and the dehydrated form of racemic cis-FTC sesquihydrate) or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, or intravenously, in liquid or solid form.

A preferred dose of the compound for HIV or HBV will be in the range from about 1 to 75 mg/kg, preferably 1 to 50 or 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The

effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.

The compound is conveniently administered in unit any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. An oral dosage of 50-1000 mg is usually convenient.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 μ M, preferably about 1.0 to 10 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.

The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.

The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as

microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.

10 The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

15 The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories, or other antivirals, including other nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other
20 synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The
25 parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

 If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

30 In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic

acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation.

Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearyl phosphatidyl ethanolamine, stearyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

What is claimed is:

- 1) A polymorphic compound of (-)-cis-FTC, wherein the compound displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern:
 - 5 a) $14.7^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $21.1^{\circ} \pm 0.1^{\circ}$, $21.8^{\circ} \pm 0.1^{\circ}$, $24.6^{\circ} \pm 0.1^{\circ}$, and $25.6^{\circ} \pm 0.1^{\circ}$ (Form II (-)-cis-FTC); or
 - b) $14.5^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $20.4^{\circ} \pm 0.1^{\circ}$, $21.4^{\circ} \pm 0.1^{\circ}$, $21.7^{\circ} \pm 0.1^{\circ}$, $25.2^{\circ} \pm 0.1^{\circ}$, and $26.2^{\circ} \pm 0.1^{\circ}$ (Form III (-)-cis-FTC).
- 2) The compound of claim 1 which is Form II (-)-cis-FTC.
- 10 3) The compound of claim 1 which is Form III (-)-cis-FTC.
- 4) The compound of claim 1 which is substantially pure Form II (-)-cis-FTC.
- 5) The compound of claim 4 which is at least 97% pure.
- 6) The compound of claim 1 which is substantially pure Form III (-)-cis-FTC.
- 7) The compound of claim 6 which is at least 97% pure.
- 15 8) A pharmaceutical composition comprising a polymorphic compound of (-)-cis-FTC, wherein the compound displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern:
 - a) $14.7^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $21.1^{\circ} \pm 0.1^{\circ}$, $21.8^{\circ} \pm 0.1^{\circ}$, $24.6^{\circ} \pm 0.1^{\circ}$, and $25.6^{\circ} \pm 0.1^{\circ}$ (Form II (-)-cis-FTC); or
 - 20 b) $14.5^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $20.4^{\circ} \pm 0.1^{\circ}$, $21.4^{\circ} \pm 0.1^{\circ}$, $21.7^{\circ} \pm 0.1^{\circ}$, $25.2^{\circ} \pm 0.1^{\circ}$, and $26.2^{\circ} \pm 0.1^{\circ}$ (Form III (-)-cis-FTC).and a pharmaceutically acceptable carrier.
- 9) A polymorphic form of (-)-cis-FTC prepared by a method comprising:
 - a) melting Form I (-)-cis-FTC, and
 - 25 b) recrystallizing the melted (-)-cis-FTC,wherein the Form I (-)-cis-FTC displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $14.1^{\circ} \pm 0.1^{\circ}$, $19.9^{\circ} \pm 0.1^{\circ}$, $20.2^{\circ} \pm 0.1^{\circ}$, $20.6^{\circ} \pm 0.1^{\circ}$, $21.0^{\circ} \pm 0.1^{\circ}$, $22.4^{\circ} \pm 0.1^{\circ}$, $28.5^{\circ} \pm 0.1^{\circ}$, $29.5^{\circ} \pm 0.1^{\circ}$, and $32.6^{\circ} \pm 0.1^{\circ}$.
- 30 10) The polymorphic form of (-)-cis-FTC of claim 9 wherein the method further comprises cooling the recrystallized FTC to below about 96°C .
- 11) A polymorphic form of (-)-cis-FTC prepared by a method comprising cooling a Form II polymorph of (-)-cis-FTC to below about 96°C , wherein the Form II


polymorph displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $14.7^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $21.1^{\circ} \pm 0.1^{\circ}$, $21.8^{\circ} \pm 0.1^{\circ}$, $24.6^{\circ} \pm 0.1^{\circ}$, and $25.6^{\circ} \pm 0.1^{\circ}$.


- 5 12) A polymorphic form of (-)-cis-FTC prepared by a method comprising heating a Form III polymorph of (-)-cis-FTC to above about 112°C , wherein the Form III polymorph displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $14.5^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $20.4^{\circ} \pm 0.1^{\circ}$, $21.4^{\circ} \pm 0.1^{\circ}$, $21.7^{\circ} \pm 0.1^{\circ}$, $25.2^{\circ} \pm 0.1^{\circ}$, and $26.2^{\circ} \pm 0.1^{\circ}$.
- 10 13) A method of preparing a polymorphic form of (-)-cis-FTC comprising:
- a) melting Form I (-)-cis-FTC, and
 - b) recrystallizing the melted (-)-cis-FTC,
- wherein the Form I (-)-cis-FTC displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $14.1^{\circ} \pm 0.1^{\circ}$, $19.9^{\circ} \pm 0.1^{\circ}$, $20.2^{\circ} \pm 0.1^{\circ}$, $20.6^{\circ} \pm 0.1^{\circ}$, $21.0^{\circ} \pm 0.1^{\circ}$, $22.4^{\circ} \pm 0.1^{\circ}$, $28.5^{\circ} \pm 0.1^{\circ}$, $29.5^{\circ} \pm 0.1^{\circ}$, and $32.6^{\circ} \pm 0.1^{\circ}$.
- 15 14) The method of claim 13 wherein the method further comprises cooling the recrystallized FTC to below about 96°C .
- 20 15) A method of preparing a polymorphic form of (-)-cis-FTC comprising cooling a Form II polymorph of (-)-cis-FTC to below about 96°C , wherein the Form II polymorph displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $14.7^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $21.1^{\circ} \pm 0.1^{\circ}$, $21.8^{\circ} \pm 0.1^{\circ}$, $24.6^{\circ} \pm 0.1^{\circ}$, and $25.6^{\circ} \pm 0.1^{\circ}$.
- 25 16) A method of preparing a polymorphic form of (-)-cis-FTC comprising heating a Form III polymorph of (-)-cis-FTC to above about 112°C , wherein the Form III polymorph displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $14.5^{\circ} \pm 0.1^{\circ}$, $16.7^{\circ} \pm 0.1^{\circ}$, $19.6^{\circ} \pm 0.1^{\circ}$, $20.4^{\circ} \pm 0.1^{\circ}$, $21.4^{\circ} \pm 0.1^{\circ}$, $21.7^{\circ} \pm 0.1^{\circ}$, $25.2^{\circ} \pm 0.1^{\circ}$, and $26.2^{\circ} \pm 0.1^{\circ}$.
- 30 17) A crystalline form of (\pm)-cis-FTC prepared by a method comprising:
- a) dissolving a first crystalline form of (\pm)-cis-FTC in water, and
 - b) recrystallizing the dissolved (\pm)-cis-FTC.


- 18) The crystalline form of (±)-cis-FTC of claim 17 wherein the method further comprises dehydrating the recrystallized (±)-cis-FTC.
- 19) The crystalline form of (±)-cis-FTC of claim 17 wherein the first crystalline form of (±)-cis-FTC is present in a composition of cis-FTC that comprises up to 98% of the (-) or (+) enantiomer.
- 20) (±)-cis-FTC sesquihydrate.
- 21) (±)-cis-FTC sesquihydrate in substantially pure form.
- 22) (±)-cis-FTC sesquihydrate in a purity of at least 97%.
- 23) A pharmaceutical composition comprising (±)-cis-FTC sesquihydrate and a pharmaceutically acceptable carrier.
- 24) Dehydrated (±)-cis-FTC sesquihydrate.
- 25) Dehydrated (±)-cis-FTC sesquihydrate in substantially pure form.
- 26) Dehydrated (±)-cis-FTC sesquihydrate in a purity of at least 97%.
- 27) A pharmaceutical composition comprising dehydrated (±)-cis-FTC sesquihydrate and a pharmaceutically acceptable carrier.
- 28) A crystalline form of (±)-cis-FTC that displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $11.5^{\circ} \pm 0.1^{\circ}$, $13.4^{\circ} \pm 0.1^{\circ}$, $19.1^{\circ} \pm 0.1^{\circ}$, $20.3^{\circ} \pm 0.1^{\circ}$, $20.8^{\circ} \pm 0.1^{\circ}$, $21.5^{\circ} \pm 0.1^{\circ}$, $21.9^{\circ} \pm 0.1^{\circ}$, and $30.9^{\circ} \pm 0.1^{\circ}$.
- 29) A crystalline form of (±)-cis-FTC that displays the following angular positions (two theta) of characteristic peaks in a powder X-ray diffraction pattern: $12.3^{\circ} \pm 0.1^{\circ}$, $14.0^{\circ} \pm 0.1^{\circ}$, $20.7^{\circ} \pm 0.1^{\circ}$, $22.6^{\circ} \pm 0.1^{\circ}$, $23.3^{\circ} \pm 0.1^{\circ}$, and $25.5^{\circ} \pm 0.1^{\circ}$.
- 30) A method of preparing a crystalline form of (±)-cis-FTC comprising:
- a) dissolving a first crystalline form of (±)-cis-FTC in water, and
- b) recrystallizing the dissolved (±)-cis-FTC.
- 31) The method of claim 30 further comprising dehydrating the recrystallized (±)-cis-FTC.
- 32) The method of claim 30 wherein the first crystalline form of (±)-cis-FTC is present in a composition of cis-FTC that comprises up to 98% of the (-) or (+) enantiomer.
- 33) Amorphous (-)-cis-FTC.
- 34) Amorphous (-)-cis-FTC in substantially pure form.
- 35) Amorphous (-)-cis-FTC in a purity of at least 97%.

- 36) A pharmaceutical composition comprising amorphous (-)-cis-FTC and a pharmaceutically acceptable carrier.
- 37) A method of preparing amorphous (-)-cis-FTC comprising:
- 5 a) melting a (-)-cis-FTC, and
- b) quench cooling the melt to avoid recrystallization.
- 38) The method of claim 37 further comprising cooling the amorphous (-)-cis-FTC to below about 96 °C.
- 39) A method of treating a HIV comprising administering to a patient afflicted with HIV a treatment effective amount of the compound of claim 1.
- 10 40) A method of treating a HBV comprising administering to a patient afflicted with HBV a treatment effective amount of the compound of claim 1.
- 41) A method of treating HIV comprising administering to a patient afflicted with HIV a treatment effective amount of (±)-cis-FTC sesquihydrate, dehydrated (±)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC.
- 15 42) A method of treating HIV comprising administering to a patient afflicted with HIV a treatment effective amount of (±)-cis-FTC sesquihydrate, dehydrated (±)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC.
- 43) Use of the compound of claim 1 in the manufacture of a medicament for the treatment of HIV.
- 20 44) Use of the compound of claim 1 in the manufacture of a medicament for the treatment of HBV.
- 45) Use of (±)-cis-FTC sesquihydrate, dehydrated (±)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC, in the manufacture of a medicament for the treatment of HIV.
- 25 46) Use of (±)-cis-FTC sesquihydrate, dehydrated (±)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC, in the manufacture of a medicament for the treatment of HBV.
- 47) A pharmaceutical composition comprising the compound of claim 1 for the treatment of HIV.
- 30 48) A pharmaceutical composition comprising the compound of claim 1 for the treatment of a HBV.


- 49) A pharmaceutical composition comprising (\pm)-cis-FTC sesquihydrate, dehydrated (\pm)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC for the treatment of HIV.
- 50) A pharmaceutical composition comprising (\pm)-cis-FTC sesquihydrate, dehydrated (\pm)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC for the treatment of HBV.
- 51) A pharmaceutical composition comprising the compound of claim 1 when used in the treatment of a HIV.
- 52) A pharmaceutical composition comprising the compound of claim 1 when used in the treatment of HBV.
- 53) A pharmaceutical composition comprising (\pm)-cis-FTC sesquihydrate, dehydrated (\pm)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC when used in the treatment of HIV.
- 54) A pharmaceutical composition comprising (\pm)-cis-FTC sesquihydrate, dehydrated (\pm)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC when used in the treatment of HBV.
- 55) Use of a pharmaceutical composition comprising the compound of claim 1 in the treatment of HIV.
- 56) Use of a pharmaceutical composition comprising the compound of claim 1 in the treatment of HBV.
- 57) Use of a pharmaceutical composition comprising (\pm)-cis-FTC sesquihydrate, dehydrated (\pm)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC in the treatment of HIV.
- 58) Use of a pharmaceutical composition comprising (\pm)-cis-FTC sesquihydrate, dehydrated (\pm)-cis-FTC sesquihydrate, or amorphous (-)-cis-FTC in the treatment of HBV.

1/15*Fig. 1*


2/15**Fig. 2**

3/15*Fig. 3*

4/15

*Fig. 4*

5/15

*Fig. 5*

6/15




Fig. 6




Fig. 7




Fig. 8






Fig. 9

*Fig 10*

*Fig. 11*







Fig. 12

*Fig. 13*

*Fig. 14*

*Fig. 15*

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/06184

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D411/04 A61K31/506 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 517 145 A (GLAXO) 9 December 1992 (1992-12-09) the whole document	1,8-16, 36-56
X	WO 95 29174 A (GLAXO) 2 November 1995 (1995-11-02) page 1 -page 10; claims 1,22	1,20-27, 36-56
X	WO 92 14743 A (EMORY) 3 September 1992 (1992-09-03) page 1 -page 29	1,8-10
X	WO 00 09494 A (TRIANGLE PHARMA.) 24 February 2000 (2000-02-24) page 1 -page 10; claims 1,12; examples 14-16	1,8-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

16 July 2002

Date of mailing of the international search report

23/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/06184

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 39 to 42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/06184

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 517145	A	09-12-1992	AP 300 A	20-01-1994
			AT 212630 T	15-02-2002
			AU 656379 B2	02-02-1995
			AU 1736192 A	11-03-1993
			AU 1881092 A	08-01-1993
			BG 60914 B1	28-06-1996
			BG 98254 A	15-07-1994
			CA 2070230 A1	04-12-1992
			CA 2311988 A1	04-12-1992
			CZ 9302612 A3	13-04-1994
			DE 69232387 D1	14-03-2002
			DK 517145 T3	06-05-2002
			WO 9221676 A1	10-12-1992
			EP 1099700 A1	16-05-2001
			EP 0517145 A1	09-12-1992
			IE 921780 A1	16-12-1992
			IL 102073 A	14-05-1996
			JP 2851480 B2	27-01-1999
			JP 6211848 A	02-08-1994
			KR 244008 B1	02-03-2000
			MX 9202619 A1	01-12-1992
			NZ 242981 A	27-04-1994
			OA 9913 A	15-09-1994
			RU 2102393 C1	20-01-1998
			SG 52455 A1	28-09-1998
			SK 125793 A3	09-11-1994
			US 5905082 A	18-05-1999
			ZA 9204007 A	28-04-1993
WO 9529174	A	02-11-1995	AP 704 A	04-12-1998
			AT 181326 T	15-07-1999
			AU 696612 B2	17-09-1998
			AU 2447195 A	16-11-1995
			BG 62810 B1	31-08-2000
			BG 100916 A	31-07-1997
			BR 9507499 A	23-09-1997
			CA 2188306 A1	02-11-1995
			CN 1149871 A	14-05-1997
			CZ 9603096 A3	16-04-1997
			DE 69510347 D1	22-07-1999
			DE 69510347 T2	18-11-1999
			DK 757684 T3	17-01-2000
			EE 9600134 A	15-04-1997
			WO 9529174 A1	02-11-1995
			EP 0757684 A1	12-02-1997
			ES 2133769 T3	16-09-1999
			FI 964251 A	22-10-1996
			GR 3031043 T3	31-12-1999
			HK 1004221 A1	11-08-2000
			HU 76296 A2	28-07-1997
			IL 113432 A	21-11-2000
			JP 10502615 T	10-03-1998
			NO 964487 A	17-12-1996
			NO 995646 A	17-11-1999
			NZ 285396 A	28-10-1998
			PL 316904 A1	17-02-1997
			RU 2158736 C2	10-11-2000
			SI 757684 T1	31-12-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/06184

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9529174	A		SK 135596 A3	09-07-1997
			US 6329522 B1	11-12-2001
			US 6051709 A	18-04-2000
			ZA 9503235 A	21-12-1995
WO 9214743	A	03-09-1992	US 5210085 A	11-05-1993
			AU 1437292 A	15-09-1992
			AU 665187 B2	21-12-1995
			AU 1561792 A	15-09-1992
			AU 679649 B2	03-07-1997
			AU 3794395 A	14-03-1996
			AU 8077398 A	15-10-1998
			BG 62053 B1	29-01-1999
			BG 98062 A	25-04-1994
			BR 9205661 A	24-05-1994
			CA 2104399 A1	23-08-1992
			CN 1065065 A ,B	07-10-1992
			CN 1127301 A	24-07-1996
			CN 1203232 A ,B	30-12-1998
			CZ 9200497 A3	17-03-1993
			EP 0575482 A1	29-12-1993
			EP 0984013 A2	08-03-2000
			FI 933684 A	06-09-1993
			HU 65548 A2	28-06-1994
			HU 9500510 A3	28-11-1995
			IE 920545 A1	26-08-1992
			IL 100965 A	31-12-1999
			JP 10147586 A	02-06-1998
			JP 2901160 B2	07-06-1999
			JP 6508605 T	29-09-1994
			KR 172590 B1	01-02-1999
			MX 9200747 A1	01-09-1992
			NO 932980 A	20-08-1993
			NZ 241625 A	26-03-1996
			NZ 250842 A	26-03-1996
			PL 169842 B1	30-09-1996
			PT 100151 A ,B	31-05-1993
			US 5814639 A	29-09-1998
			WO 9214743 A2	03-09-1992
			WO 9214729 A1	03-09-1992
			US 5892025 A	06-04-1999
			US 5852027 A	22-12-1998
			US 6069252 A	30-05-2000
			US 5700937 A	23-12-1997
			US 6346627 B1	12-02-2002
			US 6114343 A	05-09-2000
			US 5827727 A	27-10-1998
			US 5728575 A	17-03-1998
			US 5914331 A	22-06-1999
			US 5276151 A	04-01-1994
			ZA 9201251 A	20-08-1993
			PL 171150 B1	28-03-1997
WO 0009494	A	24-02-2000	AU 5675299 A	06-03-2000
			BR 9912951 A	02-10-2001
			CN 1313858 T	19-09-2001
			EP 1104415 A1	06-06-2001
			WO 0009494 A1	24-02-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/06184

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0009494	A	US 6215004 B1	10-04-2001